Apalutamide and interstitial lung disease, an association to take into account
DOI:
https://doi.org/10.32818/reccmi.a9n1a2Keywords:
interstitial lung disease, prostate cancer, apalutamide, antiandrogenic receptorAbstract
Interstitial lung disease (ILD) is a heterogeneous group of lung conditions whose etiology is varied, although toxins or other drugs can frequently cause it. Apalutamide is a selective inhibitor of androgen receptors used in cases of prostate cancer resistant to treatment with hormone blockade. There are three cases of drug-associated ILD published to date. We present a patient under treatment with apalutamide who developed a very rapid progression of ILD. An etiological diagnosis was made and treatment with high doses of corticosteroids was established, however, the patient died.
Downloads
Metrics
References
Kobe H, Tachikawa R, Masuno Y, Matsunashi A, Murata S, Hagimoto H, et al. Apalutamide-induced severe interstitial lung disease: a report of two cases from Japan. Respir Investig. 2021; 59(5): 700–705. doi: https://doi.org/10.1016/j.resinv.2021.05.006 (último acceso ene. 2024). DOI: https://doi.org/10.1016/j.resinv.2021.05.006
Kirishima F, Shigematsu Y, Kobayashi K. Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: a report of a rare case. IJU Case Rep 2022; 5(3): 153–155. doi: https://doi.org/10.1002/iju5.12420 (último acceso ene. 2024). DOI: https://doi.org/10.1002/iju5.12420
Agencia Española de Medicamentos y Productos Sanitarios. (Elreada. Autorizado 04/02/2019). Ministerio de Sanidad. CIMA. Accesible en: https://cima.aemps.es/cima/publico/detalle.html?nregistro=1181342001 (último acceso ene. 2024).
Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. The Japanese Respiratory Society Committee for formulation of Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013; 51(4): 260-277. doi: https://doi.org/10.1016/j.resinv.2013.09.001 (último acceso ene. 2024). DOI: https://doi.org/10.1016/j.resinv.2013.09.001
Smith MR, Saad F, Chowdhury S. Stéphane O. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378: 1408–1418. doi: https://doi.org/10.1056/nejmoa1715546 (último acceso ene. 2024). DOI: https://doi.org/10.1056/NEJMoa1715546
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castrationsensitive prostate cancer. N Engl J Med. 2019; 381: 13–24. doi: https://doi.org/10.1056/nejmoa1903307 (último acceso ene. 2024). DOI: https://doi.org/10.1056/NEJMoa1903307
Skeoch S, Weatherley N, Swift AJ, Oldroyd A , Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018; 7(10): 356. doi: https://doi.org/10.3390/jcm7100356 (último acceso ene. 2024). DOI: https://doi.org/10.3390/jcm7100356
Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 298(3): 550-566 doi: https://doi.org/10.1148/radiol.2021203427 (último acceso ene. 2024). DOI: https://doi.org/10.1148/radiol.2021203427
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Manuel Raya-Cruz, Rocío Córdoba-Peinado, José Juan Moreno-Sánchez, José Luis Fernández-Reyes, Francisco Gómez-Delgado
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
